Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse ModelFeb 26, 20162016 Epilepsy Pipeline Conference, San Francisco, California Christopher U. Missling, PhD View Presentation
2016 Epilepsy Pipeline Conference, San Francisco, California Christopher U. Missling, PhD View Presentation
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
